Clinical Trials Logo

Cervical Cancer clinical trials

View clinical trials related to Cervical Cancer.

Filter by:

NCT ID: NCT04008095 Recruiting - Cervical Cancer Clinical Trials

Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer

COLTEP
Start date: January 8, 2020
Phase:
Study type: Observational

A lot of studies have demonstrated the prognostic value of post therapy 18F-FDG PET/CT in the management of uterine cervical cancer. Post therapy 18F-FDG PET/CT is usually requested by a lot of clinicians. Whereas 18F-FDG PET/CT is useful for prognosis in the follow-up, data are yet insufficient to clearly establish a formal recommendation. This prospective multicenter observational study will evaluate the interest of post therapy 18F-FDG PET/CT in clinical management (within 2 months of treatment) in patients with cervical cancer at an advanced stage. Main outcome : The therapeutic impact of post therapy 18F-FDG PET/CT (within 2 months after the end of therapy) will be evaluated on the complete results included MRI. Investigators will compare : - decision of clinicians without 18F-FDG PET/CT results - and decision of clinicians knowing entire results included results of 18F-FDG PET/CT.

NCT ID: NCT04000503 Completed - Cervical Cancer Clinical Trials

Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge)

ASPIRE
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this pragmatic cluster randomized control trial is to test the effectiveness of cervical cancer screening follow-up completion using two implementation approaches for self-collected HPV testing in a rural, low-resource setting: 1) community health workers recruiting women door-to-door and 2) community health workers recruiting women at community health meetings. This study will also help to further understand how current patient referral systems are working between health facilities, patient and provider preferences for integrated care and health system related barriers to integrated cervical cancer screening. Hypothesis: More women will receive screening via the community health meeting but the engagement to care (i.e., visual inspection with acetic acid-our main outcome) will be greater in the door-to-door arm.

NCT ID: NCT04000477 Not yet recruiting - Cervical Cancer Clinical Trials

Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening Smear

ENDOCOL
Start date: March 2021
Phase: N/A
Study type: Interventional

The recommendations on the method and the realization of the cervico-uterine smears are clear. With regard to performing endocervical curettage, several methods are possible without precise consensus. In general, the Kevorkian curette is widely used. However, it is often reported by doctors and patients that curettage is painful. Some articles show that the cytobrush would be less painful. While keeping a percentage of correct curettage failures, it is sought to show that the cytobrush would improve the comfort of the patient during curettage.

NCT ID: NCT03997110 Recruiting - Cervical Cancer Clinical Trials

Palliative Radiation for Advanced Cervical Cancer

RAPPAL
Start date: June 19, 2020
Phase: N/A
Study type: Interventional

The present study is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer.

NCT ID: NCT03994055 Active, not recruiting - Cervical Cancer Clinical Trials

Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer

Start date: November 16, 2018
Phase: N/A
Study type: Interventional

During radiation therapy (RT) to pelvic tumors, the small intestine, colon and rectum are inevitably included in the radiation field and are healthy tissues that suffer damage as an adverse effect. Pelvic radiation disease (PRD) is the group of gastrointestinal symptoms experienced by patients that receive pelvic radiation. Intestinal inflammation, tissue damage, oxidative stress and tumor metabolism lead the patient to a catabolic state associated with an increase in energy demands. Also, the painful abdominal symptoms restrict the patients' food intake, leading the patients that develop PRD to an increased risk to develop protein-energy malnutrition and micronutrient deficiencies, all of which affect the patients' quality of life. Studies developed in patients with inflammatory bowel disease have suggested that probiotics may have an anti-inflammatory effect in the intestine. In addition, micronutrients and trace elements provide antioxidant capacity and exert immune-modulating effects during periods of intestinal inflammation. Thus, probiotics and immune-modulating nutrients may provide a means to diminish intestinal inflammation and symptoms associated with PRD. In this project the investigators propose that the nutritional management of cervical cancer patients be based on an anti-inflammatory diet, taking into account the nutritional status, age, comorbidities that the patient may present and symptoms developed during treatment. The nutritional intervention will include food rich in immune-modulating nutrients: omega-3 fatty acids, soluble fiber, antioxidants and polyphenols, and probiotics.

NCT ID: NCT03985072 Completed - Colorectal Cancer Clinical Trials

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

Start date: April 26, 2019
Phase: Phase 1
Study type: Interventional

The study is a Phase 1 Open-label Two-stage, Safety and Tolerability Study with Cancer Type-specific Cohorts, Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients with Advanced Solid Tumors that are Refractory to Standard Therapy or For Which No Standard Therapy Is Available. Patients with unresectable solid tumors that are refractory or have failed standard therapy and are deemed non-eligible or intolerant to further therapy or for which no standard therapy is available will be included in 5 cancer type-specific parallel cohorts. The following tumor types will be evaluated for potential inclusion in each cancer type-specific cohort: gallbladder & biliary tract carcinoma; cervical carcinoma; gastric carcinoma; pancreatic carcinoma, and colorectal carcinoma.

NCT ID: NCT03984695 Active, not recruiting - Breast Cancer Clinical Trials

Sexual Health Empowerment for Women's Health

SHE-WOMEN
Start date: November 11, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to expand the reach of an existing cervical cancer literacy and prevention intervention- the Sexual Health Empowerment (SHE) Project . As a logical extension of the investigators earlier work, the objective of this renewal is to expand reach of SHE to address women's health disparities more broadly to create a sustainable model for dissemination of health promotion interventions for vulnerable populations.

NCT ID: NCT03972722 Recruiting - Cervical Cancer Clinical Trials

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

CC
Start date: May 15, 2019
Phase: Phase 2
Study type: Interventional

Patients with recurrent or metastatic cervical cancer,and will be treated with GLS-010.

NCT ID: NCT03970083 Active, not recruiting - Cervical Cancer Clinical Trials

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

Start date: July 16, 2019
Phase:
Study type: Observational

This research is studying the level of oxygen in tumors during the brachytherapy procedure.

NCT ID: NCT03967457 Recruiting - Quality of Life Clinical Trials

Comprehensive Study on the Quality of Life in Cervical Cancer Patients

Start date: June 19, 2019
Phase:
Study type: Observational

This is prospective cohort study. All the patients with primary cervical cancer in the future three years in Peking Union Medical College Hospital will be included in this study. Before and after the major therapy (including at least radical hysterectomy and/or radiotherapy), the patients accept (1) the questionnaires survey about quality of life; (2) urodynamic testing; (3) rectum dynamics testing and (4) ovarian reserve function. The survival outcomes (disease-free survival and overall survival) will be supplemented as secondary objectives.